- Home
- SBFM vs GRI Comparison
SBFM vs GRI Comparison
Compare SBFM & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- GRI
- Stock Information
- Founded
- SBFM 2006
- GRI 2018
- Country
- SBFM United States
- GRI United States
- Employees
- SBFM N/A
- GRI N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- GRI Health Care
- Exchange
- SBFM Nasdaq
- GRI Nasdaq
- Market Cap
- SBFM 3.7M
- GRI 3.0M
- IPO Year
- SBFM N/A
- GRI N/A
- Fundamental
- Price
- SBFM $2.35
- GRI $0.77
- Analyst Decision
- SBFM
- GRI Strong Buy
- Analyst Count
- SBFM 0
- GRI 1
- Target Price
- SBFM N/A
- GRI $12.00
- AVG Volume (30 Days)
- SBFM 151.4K
- GRI 9.9M
- Earning Date
- SBFM 11-05-2024
- GRI 11-14-2024
- Dividend Yield
- SBFM N/A
- GRI N/A
- EPS Growth
- SBFM N/A
- GRI N/A
- EPS
- SBFM N/A
- GRI N/A
- Revenue
- SBFM $32,959,491.00
- GRI N/A
- Revenue This Year
- SBFM $86.70
- GRI N/A
- Revenue Next Year
- SBFM $126.76
- GRI N/A
- P/E Ratio
- SBFM N/A
- GRI N/A
- Revenue Growth
- SBFM 61.94
- GRI N/A
- 52 Week Low
- SBFM $2.25
- GRI $0.30
- 52 Week High
- SBFM $638.00
- GRI $106.29
- Technical
- Relative Strength Index (RSI)
- SBFM 25.54
- GRI 49.32
- Support Level
- SBFM $2.58
- GRI $0.79
- Resistance Level
- SBFM $2.86
- GRI $1.00
- Average True Range (ATR)
- SBFM 0.17
- GRI 0.17
- MACD
- SBFM -0.04
- GRI -0.02
- Stochastic Oscillator
- SBFM 12.67
- GRI 24.95
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.